

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 23329

Title: High-dose hepatitis B immunoglobulin therapy in HCC with HBV-DNA/HBeAg-positive patients after living donor liver transplantation

Reviewer's code: 00503228

Reviewer's country: Iraq

Science editor: Yuan Qi

Date sent for review: 2015-11-10 16:16

Date reviewed: 2015-11-13 00:34

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

- Interesting article. Please make clarification about how the 168 patients have been entered the survey. If they were consecutively included or what? - Please make a subsection in your METHODS section entitled "Inclusion & exclusion criteria" and give any criteria you have used for this. - Please Give setting of your study: If it was retrospective or prospective? If the patients randomly got assigned to the treatment dosage groups or there were any criteria for this purpose? - If authors and data analyzers were blind to the study groups or not? - Please make a subsection and give ethical concerns about your study. - Since you have found "a significant difference in the Child-Pugh score" between the groups at the baseline, you may make multivariate analyses for your findings regarding this. - Your article needs some revisions regarding scientific writing of the article. For example instead of saying "95.6%, 95.6%, and 95.6%, respectively" you can simply say "95.6% for all". - The subsection "HCC recurrence, HBV recurrence, and overall survival before propensity matching" can be simply entered into a table, and only significant or important analyses to be given. - Most figures are excessive. Please consult with someone who is experienced in the scientific writing. Only give



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

figures which represented significant disparity between the two groups. And give titles for each figure separately just above or below it. - In the limitations of the study you specify that it was not randomized. It puts a fatal limitation on the credibility of your findings. Since it wasn't randomized, so undoubtedly the physicians were putting patients on the high dose if they had worse conditions!! This limitation, unfortunately, puts a thorough shadow on your study findings.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 23329

Title: High-dose hepatitis B immunoglobulin therapy in HCC with HBV-DNA/HBeAg-positive patients after living donor liver transplantation

Reviewer's code: 00504150

Reviewer's country: Canada

Science editor: Yuan Qi

Date sent for review: 2015-11-10 16:16

Date reviewed: 2015-11-13 13:23

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The manuscript entitled, "High-dose hepatitis B immunoglobulin therapy in HCC with HBV-DNA/HBeAg-positive patients after living donor liver transplantation" is well written, and easy to read. The overall topic and study questions are relevant and of potential interest to the readers of World Journal of Gastroenterology. Retrospective nature of the study is weakness but the authors state its limitation.